8-K: Cytokinetics' Aficamten Shows Positive Results in nHCM Trial

Cytokinetics announced positive top-line results from its pivotal Phase 3 ACACIA-HCM trial of aficamten for symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), meeting both primary endpoints.

Summary

• Cytokinetics announced positive results from the ACACIA-HCM Phase 3 clinical trial of aficamten for symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
• The trial met its two primary endpoints, demonstrating statistically significant improvements in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and maximal exercise performance (pVO2) at 36 weeks compared to placebo.
• Aficamten is the first treatment to show statistically significant improvements in both patient-reported and physician-assessed endpoints in non-obstructive HCM.
• The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in the fourth quarter of 2026.
• The results were presented at the European Society of Cardiology (ESC) Congress 2026 and published in The New England Journal of Medicine.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development, indicating significant clinical success and a clear path towards a new treatment option for a patient population with unmet needs.

Positives

• The pivotal Phase 3 ACACIA-HCM trial met both dual primary endpoints, showing statistically significant improvements in KCCQ-CSS (p=0.021) and pVO2 (p=0.003) at 36 weeks compared to placebo.
• Treatment effect was consistent across prespecified subgroups for both primary endpoints.
• Key ranked secondary endpoints, including NYHA Functional Class (p<0.001) and NT-proBNP (p<0.001), also showed statistically significant improvements.
• Aficamten was generally well-tolerated, with a low rate of non-fatal adverse events leading to discontinuation (7.0% vs 1.9% for placebo).
• A global efficacy analysis demonstrated statistically significant improvements across five key domains: exercise capacity, cardiac structure, cardiac biomarkers, diastolic function, and symptom burden (p<0.001).

Negatives

• Statistical significance was not met for the endpoints of change from baseline in left atrial volume index (p=0.058) or time to first cardiovascular event (p=0.678) compared to placebo.
• LVEF <50% occurred in 10.5% of patients on aficamten compared to 0.8% on placebo.
• Serious adverse events occurred in 20.2% of patients on aficamten compared to 14.7% on placebo.
• 22 (8.5%) patients in the aficamten arm experienced a cardiovascular event compared to 20 (7.7%) in the placebo arm.

Risks

• Potential for heart failure due to systolic dysfunction, as aficamten reduces LVEF.
• Risk of drug interactions with CYP450 enzymes, potentially leading to increased or decreased aficamten concentrations.
• The MYQORZO REMS Program requires strict adherence for prescribers, patients, pharmacies, and distributors due to the risk of heart failure.
• Potential for adverse side effects or inadequate therapeutic efficacy of aficamten.
• Regulatory agencies may delay or limit clinical trials or product approval.
• Changes in standards of care or development of competitive products could render aficamten obsolete.

Future Outlook

Cytokinetics plans to submit a supplemental New Drug Application to the FDA for aficamten for the treatment of adult patients with symptomatic nHCM in the fourth quarter of 2026, following positive Phase 3 results.

Management Comments

• "ACACIA-HCM is the first-ever positive clinical trial in non-obstructive HCM. As shown in presentation and publication, the results from ACACIA-HCM are both statistically robust, consistent across prespecified subgroups and other secondary endpoints, and clinically impactful for these patients with non-obstructive HCM."
• "As such, these data may potentially translate into a new treatment option for patients with HCM with no available medical treatments that directly address their underlying disease. If approved, we look forward to seeing aficamten become the first cardiac myosin inhibitor to treat the full spectrum of symptomatic HCM."
• "We are grateful to the patient community and the clinical trial team who contributed to the successful completion of ACACIA-HCM, a fitting tribute to the patients and families who have struggled with this disease for many years and across generations."
• "We are also pleased that most of the eligible patients from ACACIA-HCM are continuing treatment with aficamten in FOREST-HCM."

Industry Context

StockSavvy.ai notes that the positive results for aficamten in non-obstructive HCM represent a significant advancement, as there are currently no approved medical treatments directly addressing the underlying disease in this patient population. This success could position Cytokinetics as a leader in the HCM therapeutic space, potentially expanding the market for cardiac myosin inhibitors.

Stakeholder Impact

• Shareholders: Potential for increased company valuation and future revenue streams if aficamten is approved for nHCM.
• Patients with nHCM: Potential access to a new, effective treatment option for their condition.
• Healthcare Providers: Availability of a novel therapy to address a significant unmet medical need.
• Competitors: Increased competitive pressure in the cardiovascular disease treatment market.

Next Steps

• Submit a supplemental New Drug Application (sNDA) to the FDA in the fourth quarter of 2026.
• Continue patient treatment in the FOREST-HCM open-label extension study.
• Host an investor event and webcast to discuss the results.

Key Dates

Recommendation

The positive and statistically significant results from the pivotal ACACIA-HCM trial, meeting both primary endpoints and demonstrating broad clinical benefit, represent a major de-risking event for aficamten in a new indication (nHCM). This significantly strengthens Cytokinetics' pipeline and commercial prospects, particularly given the lack of current treatments for nHCM. The planned sNDA submission in Q4 2026 provides a clear path to market. While some secondary endpoints were not met and safety concerns regarding LVEF reduction exist, the overall data package is compelling and addresses a substantial unmet need, warranting a strong buy recommendation.

Keywords

aficamten, ACACIA-HCM, non-obstructive hypertrophic cardiomyopathy, nHCM, cardiac myosin inhibitor, ESC Congress 2026, New England Journal of Medicine, cardiomyopathy